



Howard Backer, MD, MPH  
Interim Director

State of California—Health and Human Services Agency  
California Department of Public Health



EDMUND G. BROWN JR.  
Governor

**OFFICE OF AIDS  
AIDS Drug Assistance Program (ADAP)**

**Management Memorandum  
Memorandum Number: 2011 - 03**

June 10, 2011

TO: ADAP Local Health Jurisdiction Coordinators  
ADAP Enrollment Workers

SUBJECT: ADDITION OF RILPIVIRINE (EDURANT) 25mg TABLETS TO THE ADAP FORMULARY

**Effective June 13, 2011**, Rilpivirine (Edurant) 25mg tablets will be added to the ADAP formulary. The U.S. Food and Drug Administration has approved rilpivirine in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who are treatment naïve.

Rilpivirine belongs to a class of HIV drugs called non-nucleoside reverse transcriptase inhibitors. Rilpivirine is to be used as part of a highly active antiretroviral therapy regimen and is a pill taken once a day with food.

ADAP now has 182 drugs on the formulary.

If you have any questions regarding the addition of this medication to the ADAP formulary, please contact me at (916) 449-5943.

Celia Banda-Brown, Chief  
ADAP Section  
Office of AIDS